Systemic Anti-Cancer Therapy Regimen Library
GMALL T-LBL 1/2004 [55 years and under] - CYCLO/ARAC (LEU ALL precursor T-cell - GMALL T-LBL 1/2004 [55 years and under])
Treatment Overview
Commencing week 41.
Cycle 1 - 1 days
Intrathecal metHOTREXATe: For Ommaya reservoir reduce dose to 6 mg intraventricularly.
Cycle details
Cycle 1 - 1 days
| Medication | Dose | Route | Days | Max Duration |
|---|---|---|---|---|
| metHOTREXATe | 12 mg flat dosing | intrathecal injection | 1 | |
| cytarabine | 30 mg flat dosing | intrathecal injection | 1 | |
| hydrocortisone * | 30 mg flat dosing | intrathecal injection | 1 | |
| CYCLOPHOSPHamide | 1000 mg/m² | intravenous | 1 | 60 minutes |
| cytarabine | 500 mg/m² | intravenous | 1 | 24 hours |
Intrathecal metHOTREXATe: For Ommaya reservoir reduce dose to 6 mg intraventricularly.
Full details
Cycle 1 - 1 days
Day: 1
| Medication | Dose | Route | Max duration | Details |
|---|---|---|---|---|
| metHOTREXATe | 12 mg flat dosing | intrathecal injection |
Instructions:
Adhere to local institution policy for intrathecal administration. For Ommaya reservoir reduce dose to 6 mg intraventricularly. |
|
| cytarabine | 30 mg flat dosing | intrathecal injection |
Instructions:
Adhere to local institution policy for intrathecal administration. |
|
| hydrocortisone * | 30 mg flat dosing | intrathecal injection |
Instructions:
Adhere to local institution policy for intrathecal administration. |
|
| CYCLOPHOSPHamide | 1000 mg/m² | intravenous | 60 minutes |
Instructions:
Consider hydration with at least 2000 to 3000 ml over 24 hours as oral or IV fluid on day(s) of CYCLOPHOSPHamide and for 24 hours after or as per institutional practice. |
| cytarabine | 500 mg/m² | intravenous | 24 hours |
Supportive Care Factors
| Factor | Value |
|---|---|
| Antifungal prophylaxis: | Routine antifungal prophylaxis recommended |
| Antiviral prophylaxis for herpes virus: | Routine antiviral prophylaxis recommended |
| Emetogenicity: | Medium |
| Pneumocystis jirovecii pneumonia (PJP) prophylaxis: | Routine antibiotic prophylaxis recommended |
Antiviral prophylaxis for hepatitis B virus: Guidance is limited to high-risk anti-cancer medicines. Clinicians will need to assess individual patient risk for other anti-cancer medicines.
References
No references
* The medicines, doses, combinations, and schedule in this treatment regimen have been carefully reviewed against international best practice guidelines by specialists in medical oncology around New Zealand and this advice has been accepted for publication by Te Aho o Te Kahu (the Cancer Control Agency). Sometimes medicines that are used in routine clinical practice have not been through a formal review process by the NZ Medicines Regulator Medsafe and are therefore considered unapproved or off-label. These medicines are legally able to be prescribed through sections 25 and 29 of the Medicines Act and by obtaining informed consent from patients. All treatment regimens listed on this website have been through robust peer review and are considered an accepted standard of care, whether prescribed through sections 25 or 29 or carrying formal Medsafe Approval.
s29: This symbol indicates that some formulations of the associated medicine are legally only able to be prescribed under section 29 of the Medicines Act. You can see which formulations are section 29 by hovering over the s29 symbol. You can access full medication details from the New Zealand Formulary by clicking on the medication name. Each clinician retains full responsibility for ensuring they have complied with all relevant obligations and requirements of section 29 including obtaining informed patient consent prior to prescribing the applicable medicine.